MREO PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

MREO ▼ -3.66% at T+5d

SHORT call ✓ call won +3.66% · α vs SPY +3.74% · entry $0.2460 → $0.2370

Next anchor: T+20d due 5d ago

Last close $0.3050 (close Jun 12) · -23.98% from $0.2460 entry (call sign-flipped)

Entry anchored
May 11, 03:59 PM ET
via Databento tick

T+1d

+5.69%

call -5.69% · α -5.12%

$0.2600

settled 5w ago

T+5d

-3.66%

call +3.66% · α +3.74%

$0.2370

settled 27d ago

T+20d

—

call — · α —

—

due 5d ago

T+60d

—

call — · α —

—

in 7w

Price Chart

Loading chart...

Executive Summary

Mereo BioPharma reported Q1 2026 EPS of -$0.01, missing the $0.00 consensus estimate, with revenue not explicitly stated but net loss improving to $6.7M from $12.9M a year ago. The company highlighted ongoing regulatory discussions for setrusumab in osteogenesis imperfecta and partnership talks for alvelestat, but the Phase 3 studies for setrusumab failed to meet primary endpoints, tempering near-term catalysts.

Actionable Insight

The EPS miss and lack of revenue growth reinforce the pre-revenue clinical-stage profile. The setrusumab regulatory path remains uncertain after Phase 3 failures, and alvelestat partnership timing is unknown. Monitor for regulatory feedback on setrusumab and any partnership announcement for alvelestat, which could be a catalyst. Cash runway into mid-2027 provides some buffer but limits upside without a deal.

Key Facts

Q1 2026 EPS of -$0.01 missed consensus estimate of $0.00 (a 4100% miss vs near-zero base).
Net loss improved to $6.7M from $12.9M in Q1 2025, driven by lower G&A expenses.
Cash and cash equivalents stood at $36.2M as of March 31, 2026, down from $41.0M at year-end 2025.
Setrusumab Phase 3 studies (Orbit and Cosmic) failed to meet primary endpoints on fracture reduction, though key secondary endpoints on bone mineral density and patient-reported outcomes were met.
Company initiated regulatory agency interactions for setrusumab in pediatric OI, but no clear path to approval yet.
Alvelestat partnership discussions ongoing; Phase 3 could start within 6 months of a deal.
Vantictumab Phase 2 trial in osteopetrosis expected to start H2 2026, funded by partner āshibio.
Cash runway expected into mid-2027, excluding potential business development payments.

Financial Impact

EPS miss of $0.01 vs $0.00 consensus; net loss of $6.7M vs $12.9M YoY improvement; cash burn of ~$4.8M in Q1

epsnet losscash position

Risk Factors

Setrusumab may fail to gain regulatory approval after Phase 3 miss on primary endpoints.
Alvelestat partnership may not materialize or be on unfavorable terms.
Cash burn rate may accelerate if clinical programs expand without partner funding.
Dilution risk from potential equity offerings to fund operations beyond mid-2027.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

71% bullish (14 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3292715

3 reports for MREO

T+1T+5T+20T+60

Filters

Reports for MREO — sortable, filterable
	Type				Now
Jun 11, 2026 3d ago	Institutional Cluster NEUTRAL ★ 4/10	$0.3024 awaiting T+5	awaiting T+5	—	$0.3050 (+0.86%)
May 12, 2026 4w ago	Press Release BEARISH ★ 6/10	$0.2460 $0.2370	▲ +3.66%	▲ +3.74%	$0.3050 (−23.98%)
Mar 19, 2026 12w ago	Press Release MIXED ★ 6/10	$0.3610 $0.3390	▼ −6.09%	▼ −3.88%	$0.3050 (−15.51%)

US Market Status

Market Closed — Opens in 5h 4m

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access